Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. has announced several significant changes, including an increase in registered capital following a successful placement of new H shares, which raises their total issued share capital. Additionally, the company plans to abolish its Board of Supervisors, with its powers being transferred to the Audit Committee, in response to updates in Chinese corporate law. The company also proposes amendments to its Articles of Association and internal policies to align with the latest legal requirements and improve operational efficiency. These changes are expected to streamline governance and enhance compliance with regulatory standards, potentially impacting the company’s market positioning and stakeholder relations.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, primarily engaged in the research, development, and commercialization of innovative therapeutics. The company focuses on the pharmaceutical industry, particularly in the development of drugs for cancer, autoimmune, and infectious diseases.
Average Trading Volume: 13,773,473
Technical Sentiment Signal: Buy
Current Market Cap: HK$48.06B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.